Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Luye Pharma Group stock price, quote, forecast and news

2186.HK
BMG570071099
A116Z9

Price

2.56 CNY
Today +/-
+0 CNY
Today %
+0 %
P

Luye Pharma Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Luye Pharma Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Luye Pharma Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Luye Pharma Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Luye Pharma Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Luye Pharma Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Luye Pharma Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Luye Pharma Group’s growth potential.

Luye Pharma Group Revenue, EBIT and net profit per share

DateLuye Pharma Group RevenueLuye Pharma Group EBITLuye Pharma Group Net Income
2026e8.27 B CNY1.75 B CNY1.09 B CNY
2025e7.53 B CNY1.51 B CNY884.41 M CNY
2024e6.79 B CNY1.31 B CNY677.21 M CNY
20236.14 B CNY1.03 B CNY532.61 M CNY
20225.98 B CNY916.53 M CNY604.81 M CNY
20215.2 B CNY435.54 M CNY-134.39 M CNY
20205.54 B CNY1.19 B CNY706.59 M CNY
20196.36 B CNY1.74 B CNY1.4 B CNY
20185.17 B CNY1.52 B CNY1.3 B CNY
20173.81 B CNY1.09 B CNY981.37 M CNY
20162.92 B CNY914.71 M CNY891.54 M CNY
20152.56 B CNY830.93 M CNY754.52 M CNY
20142.54 B CNY718.95 M CNY605.52 M CNY
20132.52 B CNY402.3 M CNY310.5 M CNY
20122.14 B CNY279.1 M CNY169 M CNY
20111.77 B CNY218.8 M CNY151.6 M CNY
20101.34 B CNY183 M CNY136.1 M CNY
2009954.8 M CNY155.1 M CNY123.5 M CNY
2008651 M CNY85.3 M CNY62.1 M CNY
2007509 M CNY82.1 M CNY58.1 M CNY
2006308.3 M CNY81.1 M CNY83.7 M CNY
2005344.4 M CNY91.7 M CNY89.6 M CNY
2004315.4 M CNY80.8 M CNY71.8 M CNY

Luye Pharma Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B CNY)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B CNY)EBIT (B CNY)EBIT MARGIN (%)NET INCOME (B CNY)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.240.320.340.310.510.650.951.341.772.142.522.542.562.923.815.176.365.545.25.986.146.797.538.27
-32.359.21-10.4765.2627.9046.5440.4632.3920.3517.801.110.7913.8130.7535.6322.89-12.87-6.1215.022.7110.5610.849.90
54.6265.7177.6279.2284.0983.1085.7484.7883.0383.5683.5481.0581.4381.6677.6978.2776.7572.0365.3169.2268.44---
0.130.210.270.240.430.540.821.141.471.782.12.062.092.382.964.054.883.993.44.144.2000
0.060.080.090.080.080.090.160.180.220.280.40.720.830.911.091.521.741.190.440.921.031.311.511.75
23.9525.4026.4526.3016.1113.0616.2513.6612.2913.0715.9828.2332.3831.3328.5829.3827.4221.478.3715.3216.8319.2420.0321.20
0.040.070.090.080.060.060.120.140.150.170.310.610.750.890.981.31.40.71-0.130.60.530.680.881.09
-69.0525.35-6.74-30.126.9098.3910.5711.0311.9283.4395.1624.6318.1710.1032.827.14-49.43-118.98-550.75-11.9227.2630.5823.19
0.320.30.410.460.490.490.490.490.492.652.652.993.323.323.263.223.223.193.453.483.73000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Luye Pharma Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Luye Pharma Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M CNY)RECEIVABLES (M CNY)OTHER REC. (M CNY)INVENTORIES (M CNY)OTHER CURRENT LIAB. (M CNY)CURRENT ASSETS (M CNY)TANGIBLE ASSETS (M CNY)LONG-T. INVEST. (M CNY)LONG-T. REC. (M CNY)INTANGIBLE ASSETS (M CNY)GOODWILL (M CNY)OTHER NON-CURRENT ASSETS (M CNY)NON-CURRENT ASSETS (M CNY)TOTAL ASSETS (M CNY)LIABILITIESCOMMON STOCK (M CNY)ADDITIONAL PAID-IN CAPITAL (M CNY)RETAINED EARNINGS (M CNY)OTHER EQUITY (M CNY)UNREAL. GAINS/LOSSES (M CNY)EQUITY (M CNY)LIABILITIES (M CNY)PROVISIONS (M CNY)OTHER SHORT-TERM LIAB. (M CNY)SHORT-TERM DEBTS (M CNY)LONG-TERM DEBT PORTION (M CNY)SHORT-TERM REC. (M CNY)LONG-T. LIAB. (M CNY)DEFERRED TAXES (M CNY)OTHER LIAB. (M CNY)LONG-T. LIABILITIES (M CNY)DEBT (M CNY)TOTAL CAPITAL (M CNY)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Luye Pharma Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Luye Pharma Group's financial health and stability.

Assets

Luye Pharma Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Luye Pharma Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Luye Pharma Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Luye Pharma Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B CNY)DEPRECIATION (M CNY)DEFERRED TAXES (M CNY)CHANGES IN WORKING CAPITAL (M CNY)NON-CASH ITEM (M CNY)PAID INTEREST (M CNY)PAID TAXES (M CNY)NET CASH FLOW FROM OPERATING ACTIVITIES (B CNY)CAPITAL EXPENDITURES (M CNY)CASH FLOW FROM INVESTING ACTIVITIES (M CNY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B CNY)INTEREST INCOME AND EXPENSES (M CNY)NET DEBT CHANGE (B CNY)NET CHANGE IN EQUITY (B CNY)CASH FLOW FROM FINANCING ACTIVITIES (B CNY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B CNY)TOTAL DIVIDENDS PAID (M CNY)NET CHANGE IN CASH FLOW (B CNY)FREE CASH FLOW (M CNY)SHARE-BASED COMPENSATION (M CNY)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
0.050.080.090.090.070.080.170.20.20.260.380.730.90.971.121.471.630.94-0.070.67
1010111540414465747895105109135243310455510581671
00000000000000000000
-27-43-56-4418-16-441130-211-66-519-535-469-360-822-869-791-985-142
740-4110-2-181929277-78-48-3483202371660454
652216128922342640132951157207330297369
50071015223859707810311113219517817616027092
0.040.050.050.050.140.110.160.250.330.150.440.320.390.590.961.051.421.030.181.65
-13-11-29-9-14-44-24-140-338-147-270-289-208-319-625-2,484-3,050-1,519-1,541-1,163
-12-15-44-343-176-3-66-194-643-135-554-2,978240-1,834-743-2,997-2,628138-3,436-1,658
0-0-0.02-0.33-0.160.04-0.04-0.05-0.30.01-0.28-2.690.45-1.52-0.12-0.510.421.66-1.89-0.49
00000000000000000000
0.02-0.07-0.050.010.11-0.110.060.060.180.020.27-0.440.21.121.243.282.331.44-0.41-0.67
00.100.32-0000000000-0.46-0.02-0.01-0.081.040
00.05-0.060.320.09-0.130.060.060.170.090.092.660.050.820.732.41.840.251.880.05
-0.020.01-0.01-0.02-0.02-0.0100-0.010.08-0.19-0.04-0.15-0.190.17-0.56-0.1-0.931.240.72
0000000000000-106-212-289-376-17500
0.030.08-0.060.030.05-0.020.160.12-0.150.11-0.03-00.69-0.450.870.410.631.54-1.43-0.11
27.136.516.241.6121.561.6138.7113.6-13.25.8168.729.82186.62272.89338.92-1,438.93-1,628.33-486.43-1,359.22490.14
00000000000000000000

Luye Pharma Group stock margins

The Luye Pharma Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Luye Pharma Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Luye Pharma Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Luye Pharma Group's sales revenue. A higher gross margin percentage indicates that the Luye Pharma Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Luye Pharma Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Luye Pharma Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Luye Pharma Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Luye Pharma Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Luye Pharma Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Luye Pharma Group Margin History

Luye Pharma Group Gross marginLuye Pharma Group Profit marginLuye Pharma Group EBIT marginLuye Pharma Group Profit margin
2026e68.44 %21.2 %13.17 %
2025e68.44 %20.03 %11.75 %
2024e68.44 %19.24 %9.97 %
202368.44 %16.83 %8.67 %
202269.22 %15.32 %10.11 %
202165.32 %8.38 %-2.58 %
202072.04 %21.47 %12.76 %
201976.74 %27.42 %21.96 %
201878.27 %29.38 %25.19 %
201777.68 %28.57 %25.73 %
201681.66 %31.35 %30.56 %
201581.44 %32.42 %29.44 %
201481.03 %28.26 %23.8 %
201383.56 %16 %12.35 %
201283.53 %13.07 %7.91 %
201183.03 %12.33 %8.54 %
201084.76 %13.65 %10.15 %
200985.76 %16.24 %12.93 %
200883.18 %13.1 %9.54 %
200784.24 %16.13 %11.41 %
200679.4 %26.31 %27.15 %
200577.79 %26.63 %26.02 %
200465.69 %25.62 %22.76 %

Luye Pharma Group Stock Sales Revenue, EBIT, Earnings per Share

The Luye Pharma Group earnings per share therefore indicates how much revenue Luye Pharma Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Luye Pharma Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Luye Pharma Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Luye Pharma Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Luye Pharma Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Luye Pharma Group Revenue, EBIT and net profit per share

DateLuye Pharma Group Sales per ShareLuye Pharma Group EBIT per shareLuye Pharma Group Earnings per Share
2026e2.2 CNY0 CNY0.29 CNY
2025e2 CNY0 CNY0.24 CNY
2024e1.81 CNY0 CNY0.18 CNY
20231.65 CNY0.28 CNY0.14 CNY
20221.72 CNY0.26 CNY0.17 CNY
20211.51 CNY0.13 CNY-0.04 CNY
20201.73 CNY0.37 CNY0.22 CNY
20191.97 CNY0.54 CNY0.43 CNY
20181.61 CNY0.47 CNY0.4 CNY
20171.17 CNY0.33 CNY0.3 CNY
20160.88 CNY0.28 CNY0.27 CNY
20150.77 CNY0.25 CNY0.23 CNY
20140.85 CNY0.24 CNY0.2 CNY
20130.95 CNY0.15 CNY0.12 CNY
20120.8 CNY0.11 CNY0.06 CNY
20113.6 CNY0.44 CNY0.31 CNY
20102.72 CNY0.37 CNY0.28 CNY
20091.94 CNY0.31 CNY0.25 CNY
20081.32 CNY0.17 CNY0.13 CNY
20071.03 CNY0.17 CNY0.12 CNY
20060.67 CNY0.18 CNY0.18 CNY
20050.84 CNY0.22 CNY0.22 CNY
20041.05 CNY0.27 CNY0.24 CNY

Luye Pharma Group business model

The Luye Pharma Group Ltd is a leading company in the pharmaceutical industry that offers a wide range of high-quality therapeutics and healthcare products to its customers. The company was founded in 1994 and is headquartered in Yantai, China. The history of the Luye Pharma Group Ltd dates back to 1994 when it was established as a small research and development unit. Since then, the company has grown into a global corporation operating in over 80 countries. In recent years, the Luye Pharma Group Ltd has expanded its drug manufacturing through the integration of CDMO Services and has also been involved in many mergers and acquisitions. The business model of the Luye Pharma Group Ltd is based on a wide product portfolio that encompasses research and development as well as manufacturing. The company has a strong product portfolio in the areas of neurology, oncology, cardiometabolic diseases, and sleep medicine. Its various business units work on the development, production, and marketing of innovative medications and healthcare products. The Luye Pharma Group Ltd is divided into several divisions specialized in meeting the requirements and needs of different customers: 1. Neurology: This division focuses on the research and development of medications for the treatment of neurological disorders and psychiatric conditions. The company offers a variety of products for epilepsy, Alzheimer's disease, Parkinson's disease, and depression. 2. Oncology: This division develops and manufactures drugs for the treatment of cancer. The company has a range of products for breast cancer, bladder cancer, prostate cancer, and lung cancer. 3. Cardiometabolic Diseases: This division offers a product range that includes medications for the treatment of diabetes and hypertension, as well as for the prevention and treatment of cardiovascular diseases. 4. Sleep Medicine: This division provides a wide portfolio of sleep and sedative medications without the well-known side effects such as sedation or respiratory problems. The company is also focusing on technologies such as nanoparticles, probiotics, and new delivery forms to further enhance the category of medications. Luye Pharma Group Ltd offers a wide range of high-quality medications and healthcare products. Some of its well-known products include Seroquel XR for the treatment of depression and bipolar disorders, Lipusuap for the treatment of breast cancer, Zuclopenthoxil hydrochloride for the treatment of schizophrenia, Cozaar for the treatment of hypertension, Risperidone for the treatment of psychotic disorders, and Yitian as a natural sleep aid. In summary, the Luye Pharma Group Ltd is a leading manufacturer of medications and healthcare products with a wide product range ranging from neurology to oncology and sleep and sedative therapeutics. The company is headquartered in Yantai, China, and is represented in over 80 countries. The Luye Group has strengthened its position in the global market through numerous acquisitions in recent years. Luye Pharma Group is one of the most popular companies on Eulerpool.com.

Luye Pharma Group SWOT Analysis

Strengths

Luye Pharma Group Ltd has several strengths that contribute to its success in the market. The company has a diverse portfolio of pharmaceutical products, allowing it to cater to a wide range of medical needs. Additionally, Luye Pharma Group has a strong presence in both domestic and international markets, leveraging its global reach for growth and expansion.

Furthermore, the company has established strategic partnerships and collaborations with various healthcare organizations, enabling Luye Pharma Group to access new markets, technologies, and distribution channels. This strengthens its competitive advantage and enhances its overall market position.

Weaknesses

Despite its strengths, Luye Pharma Group Ltd also faces certain weaknesses that may hinder its progress. One weakness is its heavy reliance on a few key products for revenue generation. This concentration of sales poses a potential risk if market conditions change or if new competitors enter the market.

In addition, the company may face challenges in terms of regulatory compliance and intellectual property protection, especially when operating in different jurisdictions. These weaknesses could impede Luye Pharma Group's growth prospects and expose it to legal and regulatory risks.

Opportunities

Luye Pharma Group Ltd has various opportunities that it can capitalize on to further expand its business. The growing global pharmaceutical market presents significant potential for revenue growth. By leveraging its strong R&D capabilities, the company can develop innovative drugs to address unmet medical needs and tap into new therapeutic areas.

Furthermore, Luye Pharma Group can consider strategic acquisitions and partnerships to enhance its product portfolio and market presence. Collaborations with research institutions and universities can also provide access to cutting-edge technology and expertise, facilitating continued innovation and growth.

Threats

Luye Pharma Group Ltd faces threats that could pose risks to its business operations and market position. Intense competition within the pharmaceutical industry, both from existing players and emerging companies, presents a challenge for the company. This competition can potentially impact Luye Pharma Group's market share and pricing strategy.

Additionally, the regulatory landscape and pricing pressures in different markets may affect the company's profitability. Changes in regulations, such as drug approval processes or pricing policies, can create uncertainties and increase operational costs for Luye Pharma Group.

Luye Pharma Group historical P/E ratio, EBIT, and P/S ratio.

Luye Pharma Group shares outstanding

The number of shares was Luye Pharma Group in 2023 — This indicates how many shares 3.728 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Luye Pharma Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Luye Pharma Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Luye Pharma Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Luye Pharma Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Luye Pharma Group dividend history and estimates

In 2023, Luye Pharma Group paid a dividend amounting to 0 CNY. Dividend means that Luye Pharma Group distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Luye Pharma Group provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Luye Pharma Group’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Luye Pharma Group's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Luye Pharma Group Dividend History

DateLuye Pharma Group Dividend
20200.06 CNY
20190.13 CNY
20180.11 CNY
20170.07 CNY
20160.04 CNY

Luye Pharma Group dividend payout ratio

In 2023, Luye Pharma Group had a payout ratio of 27.82%. The payout ratio indicates the percentage of the company's profits that Luye Pharma Group distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Luye Pharma Group represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Luye Pharma Group could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Luye Pharma Group's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Luye Pharma Group Payout Ratio History

DateLuye Pharma Group Payout ratio
2026e28 %
2025e28.12 %
2024e28.05 %
202327.82 %
202228.49 %
202127.85 %
202027.12 %
201930.48 %
201825.96 %
201723.91 %
201613.78 %
201527.85 %
201427.85 %
201327.85 %
201227.85 %
201127.85 %
201027.85 %
200927.85 %
200827.85 %
200727.85 %
200627.85 %
200527.85 %
200427.85 %
Unfortunately, there are currently no price targets and forecasts available for Luye Pharma Group.

Eulerpool ESG Scorecard© for the Luye Pharma Group stock

Eulerpool World ESG Rating (EESG©)

74/ 100

🌱 Environment

95

👫 Social

63

🏛️ Governance

64

Environment

Scope 1 - Direct Emissions
10,822.51
Scope 2 - Indirect emissions from purchased energy
67,258.94
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
78,081.45
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees53.187
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Luye Pharma Group list of shareholders

%
Name
Stocks
Change
Date
4.91 % E Fund Management Co. Ltd.184,787,500-7,958,5008/10/2023
33.47 % Luye Life Sciences Group Ltd.1,259,196,70304/10/2024
2.43 % ZhongGeng Fund Management Co., Ltd.91,319,50091,319,5006/30/2023
14.68 % Hillhouse Capital Management Ltd.552,324,10802/22/2023
1.53 % The Vanguard Group, Inc.57,397,45603/31/2024
1.12 % Bosera Asset Management Co., Ltd.42,229,00010,303,00012/31/2023
1.06 % GF Fund Management Co., Ltd.39,926,50019,217,00012/31/2023
0.93 % Dimensional Fund Advisors, L.P.34,874,500-1,437,5002/29/2024
0.65 % BlackRock Institutional Trust Company, N.A.24,607,00042,0003/31/2024
0.62 % FIL Investment Management (Hong Kong) Limited23,238,75023,238,7508/29/2023
1
2
3
4
5
...
9

Luye Pharma Group Executives and Management Board

Mr. Dian Bo Liu57
Luye Pharma Group Executive Chairman of the Board, Chief Executive Officer
Compensation 3.16 M CNY
Mr. Rong Bing Yang57
Luye Pharma Group Executive Vice Chairman of the Board (since 2003)
Compensation 2.87 M CNY
Mr. Hui Xian Yuan64
Luye Pharma Group Executive Director
Compensation 1.47 M CNY
Ms. Yuan Yuan Zhu42
Luye Pharma Group Executive Director (since 2014)
Compensation 1.38 M CNY
Mr. Man Kit Leung69
Luye Pharma Group Non-Executive Independent Director
Compensation 309,000 CNY
1
2
3

Luye Pharma Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Essence Info A Stock
Essence Info A
SupplierCustomer0,700,900,870,830,76-
Lotus Pharmaceutical Stock
Lotus Pharmaceutical
SupplierCustomer0,620,58-0,69-0,70-0,31-0,56
PharmaMar Stock
PharmaMar
SupplierCustomer0,530,53-0,84-0,820,450,53
Cipla Stock
Cipla
SupplierCustomer0,370,78-0,50-0,74-0,21-0,44
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,460,07-0,86-0,89-0,69-0,62
Zhejiang Jiuzhou Pharm A Stock
Zhejiang Jiuzhou Pharm A
SupplierCustomer-0,52-0,07-0,340,42-0,24-0,43
Ocumension Stock
Ocumension
SupplierCustomer-0,770,210,330,780,92-
Towa Pharmaceutical Stock
Towa Pharmaceutical
SupplierCustomer-0,84-0,160,780,39-0,26-0,48
1

Most common questions regarding Luye Pharma Group

What values and corporate philosophy does Luye Pharma Group represent?

Luye Pharma Group Ltd is a renowned pharmaceutical company that upholds strong values and a distinct corporate philosophy. The company focuses on improving the well-being of individuals by providing innovative and high-quality healthcare solutions. Luye Pharma Group Ltd is committed to meeting healthcare needs globally and believes in continuous research and development to deliver cutting-edge pharmaceutical products. With a customer-centric approach, they strive for excellence in manufacturing and commercialization, ensuring affordable and accessible healthcare options. Luye Pharma Group Ltd's core values include integrity, innovation, collaboration, and customer satisfaction, which guide their operations and drive their success in the pharmaceutical industry.

In which countries and regions is Luye Pharma Group primarily present?

Luye Pharma Group Ltd is primarily present in multiple countries and regions worldwide. These include China, where the company is headquartered, as well as the United States, Europe, Asia-Pacific, and other emerging markets. With a global presence, Luye Pharma Group Ltd has established a strong international footprint to cater to diverse markets and provide innovative pharmaceutical solutions.

What significant milestones has the company Luye Pharma Group achieved?

Luye Pharma Group Ltd has achieved several significant milestones. In recent years, the company has successfully expanded its global presence by establishing strategic partnerships and acquiring new assets. Luye Pharma has also made remarkable advances in research and development, with numerous new drug approvals and clinical trial successes. Furthermore, the company has continuously increased its revenue and market share, solidifying its position as a leading pharmaceutical enterprise. Luye Pharma Group Ltd's commitment to innovation and growth has propelled it to become a trusted name in the pharmaceutical industry, inspiring confidence among investors and stakeholders alike.

What is the history and background of the company Luye Pharma Group?

Luye Pharma Group Ltd is a renowned pharmaceutical company with a rich history and background. Established in 1994, Luye Pharma Group has consistently grown and evolved into a leading player in the global pharmaceutical industry. The company is dedicated to developing, manufacturing, and marketing a wide range of innovative and high-quality healthcare products. Luye Pharma Group operates in over 80 countries and regions, with a strong presence in the fields of oncology, cardiovascular, neuropsychiatry, and more. With a commitment to research and development, Luye Pharma Group continues to create sustainable solutions for the ever-changing pharmaceutical landscape, ensuring better health outcomes for people worldwide.

Who are the main competitors of Luye Pharma Group in the market?

Some of the main competitors of Luye Pharma Group Ltd in the market include multinational pharmaceutical companies like Pfizer, Novartis, and Bristol-Myers Squibb. These companies have a strong presence in the global pharmaceutical industry and offer a wide range of products and therapeutic solutions similar to Luye Pharma Group Ltd. However, Luye Pharma Group Ltd has established its unique position in the market through its focus on developing and commercializing innovative drugs and therapeutic solutions, particularly in the areas of oncology, cardiovascular, and central nervous system disorders.

In which industries is Luye Pharma Group primarily active?

Luye Pharma Group Ltd is primarily active in the pharmaceutical industry.

What is the business model of Luye Pharma Group?

Luye Pharma Group Ltd operates under a pharmaceutical business model. The company is primarily focused on the research, development, production, and sale of pharmaceutical products. Luye Pharma Group Ltd specializes in developing and commercializing innovative medicines and therapies in various therapeutic areas. They aim to address unmet medical needs and improve patient outcomes. With their extensive product portfolio, Luye Pharma Group Ltd strives to provide high-quality pharmaceutical solutions globally. By constantly investing in research and development, they aim to stay at the forefront of medical advancements and deliver effective and safe treatments to patients worldwide.

What is the P/E ratio of Luye Pharma Group 2024?

The Luye Pharma Group P/E ratio is 14.08.

What is the P/S ratio of Luye Pharma Group 2024?

The Luye Pharma Group P/S ratio is 1.4.

What is the AlleAktien quality score of Luye Pharma Group?

The AlleAktien quality score for Luye Pharma Group is 3/10.

What is the revenue of Luye Pharma Group 2024?

The expected Luye Pharma Group revenue is 6.79 B CNY.

How high is the profit of Luye Pharma Group 2024?

The expected Luye Pharma Group profit is 677.21 M CNY.

What is the business model of Luye Pharma Group

Luye Pharma Group Ltd is an internationally operating pharmaceutical company based in China. The company specializes in the development, production, and marketing of innovative drugs and generics in various therapeutic areas. Luye Pharma operates in four main business areas: new drugs and biosimilars, generics, medical devices, and health services. The company aims to offer innovative and cost-effective medications and healthcare services to meet the needs of patients worldwide. Luye Pharma has a strong presence in the global market due to its strong pipeline of products and wide portfolio of existing drugs and devices. The company remains an innovator and a leading player in the global pharmaceutical industry through its continuous investment in research and development.

What is the Luye Pharma Group dividend?

Luye Pharma Group pays a dividend of 0 CNY distributed over payouts per year.

How often does Luye Pharma Group pay dividends?

The dividend cannot currently be calculated for Luye Pharma Group or the company does not pay out a dividend.

What is the Luye Pharma Group ISIN?

The ISIN of Luye Pharma Group is BMG570071099.

What is the Luye Pharma Group WKN?

The WKN of Luye Pharma Group is A116Z9.

What is the Luye Pharma Group ticker?

The ticker of Luye Pharma Group is 2186.HK.

How much dividend does Luye Pharma Group pay?

Over the past 12 months, Luye Pharma Group paid a dividend of 0.06 CNY . This corresponds to a dividend yield of about 2.35 %. For the coming 12 months, Luye Pharma Group is expected to pay a dividend of 0 CNY.

What is the dividend yield of Luye Pharma Group?

The current dividend yield of Luye Pharma Group is 2.35 %.

When does Luye Pharma Group pay dividends?

Luye Pharma Group pays a quarterly dividend. This is distributed in the months of October, July, October, July.

How secure is the dividend of Luye Pharma Group?

Luye Pharma Group paid dividends every year for the past 3 years.

What is the dividend of Luye Pharma Group?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Luye Pharma Group located?

Luye Pharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Luye Pharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Luye Pharma Group from 7/24/2020 amounting to 0.06 CNY, you needed to have the stock in your portfolio before the ex-date on 6/29/2020.

When did Luye Pharma Group pay the last dividend?

The last dividend was paid out on 7/24/2020.

What was the dividend of Luye Pharma Group in the year 2023?

In the year 2023, Luye Pharma Group distributed 0 CNY as dividends.

In which currency does Luye Pharma Group pay out the dividend?

The dividends of Luye Pharma Group are distributed in CNY.

All fundamentals about Luye Pharma Group

Our stock analysis for Luye Pharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Luye Pharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.